Agilent Technologies, Inc. (NYSE:A) is set to announce its fourth-quarter fiscal 2026 results on November 23, following the close of trading. The company, known for its contributions to the life sciences, diagnostics, and applied chemical markets, has shown a pattern of surpassing earnings expectations, as evidenced by its performance in the previous quarter. Agilent reported an adjusted earnings per share (EPS) of $1.62, exceeding the Zacks Consensus Estimate by 9.46%. Over the past four quarters, the company has outperformed estimates twice, matched once, and missed once, resulting in an average earnings surprise of 3.79%.
The Zacks Consensus Estimate for Agilent’s upcoming quarterly revenue is approximately $1.99 billion, representing a 6.7% increase compared to the same period last year. The consensus for EPS is $1.72, indicating an 8.2% rise from the previous year’s figure. These estimates reflect the company’s ongoing efforts to maintain growth across its diverse product lines and market segments.
Performance and Market Expectations
Agilent’s Life Sciences and Diagnostics Markets Group (LDG) segment is expected to benefit from ongoing growth in its Liquid Chromatography (LC) and specialty contract development and manufacturing (CDMO) businesses within the Advanced Therapeutics Division (ATD). However, growth in the ATD segment may be moderate due to challenging year-over-year comparisons, given the previous year’s over 40% growth. This segment plays a crucial role in Agilent’s portfolio, providing essential tools and technologies for research and development in pharmaceuticals and biotechnology.
In the third fiscal quarter, Agilent’s applied markets portfolio demonstrated robust growth, particularly in China, which saw a 9% increase, surpassing management’s expectations for flat growth. The rise in AI-related capital investments in China has bolstered demand for Agilent’s gas chromatography (GC), GC/MS, and spectroscopy products. Additionally, the new 9500 triple-quadrupole ICP-MS has gained traction, especially among semiconductor supply-chain customers, contributing to a strong order pipeline. These developments highlight Agilent’s ability to adapt to market trends and leverage technological advancements to drive sales.
In the biopharma sector, the adoption of Altura columns by new accounts is anticipated to support revenue growth. The cancer diagnostics business is also expected to benefit from strong growth in companion diagnostics and genomics. Agilent’s antibody portfolio, focused on clinical applications, is likely to further expand its pathology business. This expansion is crucial as it aligns with the growing demand for precision medicine and personalized healthcare solutions.
Analytical and Clinical Group Performance
The Analytical and Clinical Group (ACG) reported core revenue growth exceeding 5%, slightly ahead of management’s forecast. This growth was driven by strong performance in consumables, with an expanded installed base facilitating further adoption. Service revenue growth, following the initial warranty period, provided an additional boost and these trends are expected to continue into the upcoming quarter. The group’s ability to maintain momentum in consumables and services is indicative of Agilent’s strategic focus on customer retention and recurring revenue streams.
Market Analysis and Stock Performance
According to Zacks Investment Research, a stock with a Zacks Rank of #1 (Strong Buy), #2 (Buy), or #3 (Hold), combined with a positive Earnings ESP, is more likely to exceed earnings estimates. Agilent Technologies currently holds a Zacks Rank of #4 (Sell) and an Earnings ESP of +0.19%, suggesting a lower probability of surpassing expectations in the upcoming earnings report. This ranking reflects the challenges Agilent faces in meeting market expectations despite its solid operational performance.
In the broader medical technology sector, TG Therapeutics (NASDAQ:TGTX) is highlighted as a noteworthy stock, with an Earnings ESP of +71.43% and a Zacks Rank #1. The company is scheduled to release its third-quarter 2026 results on November 9. Despite a mixed performance in previous quarters, TG Therapeutics has shown significant earnings surprises, with an average of 184.65%. This performance underscores the volatility and potential for growth within the biotech sector.
Other companies in the sector, such as Aardvark Therapeutics (NASDAQ:AARD) and Caribou Biosciences (NASDAQ:CRBU), also present potential investment opportunities, each with positive Earnings ESPs and varying Zacks Ranks. These companies are part of a dynamic industry landscape where innovation and strategic positioning can lead to substantial financial performance.
Investors and analysts will be closely monitoring Agilent Technologies’ upcoming earnings release to assess the company’s financial health and future growth prospects, particularly in light of its recent performance and market conditions. The results will provide insights into Agilent’s ability to sustain its growth trajectory and adapt to evolving market demands.
Footnotes:
- Agilent Technologies is set to release its Q4 fiscal 2026 results on November 23, 2026. Source.
- The Zacks Consensus Estimate for Agilent’s Q4 revenue is $1.99 billion, a 6.7% increase from the previous year. Source.
- Agilent’s Life Sciences and Diagnostics Markets Group is expected to benefit from growth in its LC and CDMO businesses. Source.
- TG Therapeutics has an Earnings ESP of +71.43% and a Zacks Rank #1. Source.
Featured Image: Megapixl @ Warenemy
